These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 24975701)

  • 1. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
    Oldenburg J; Austin SK; Kessler CM
    Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
    Santagostino E
    Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
    Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?
    Ettingshausen CE; Kreuz W
    Haemophilia; 2013 Jan; 19 Suppl 1():12-7. PubMed ID: 23278995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of VWF for the success of immune tolerance induction.
    Kreuz W
    Thromb Res; 2008; 122 Suppl 2():S7-S12. PubMed ID: 18549910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors: our greatest challenge. Can we minimize the incidence?
    Kruse-Jarres R
    Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New predictive approaches for ITI treatment.
    Minno GD; Santagostino E; Pratt K; Königs C
    Haemophilia; 2014 Sep; 20 Suppl 6():27-43. PubMed ID: 24975702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
    Gringeri A
    Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
    Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
    Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges of the management of severe hemophilia A with inhibitors: two case reports emphasizing the potential interest of a high-purity human Factor VIII/von Willebrand factor concentrate and individually tailored prophylaxis guided by thrombin-generation test.
    Mathieu S; Crampe C; Dargaud Y; Lavigne-Lissalde G; Escuriola-Ettingshausen C; Tardy B; Meley R; Thouvenin S; Stephan JL; Berger C
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):940-5. PubMed ID: 26517064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors.
    Kurth MA; Dimichele D; Sexauer C; Sanders JM; Torres M; Zappa SC; Ragni M; Leonard N
    Haemophilia; 2008 Jan; 14(1):50-5. PubMed ID: 17941829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.
    Kurth M; Puetz J; Kouides P; Sanders J; Sexauer C; Bernstein J; Gruppo R; Manco-Johnson M; Neufeld EJ; Rodriguez N; Wicklund B; Quon D; Aledort L
    J Thromb Haemost; 2011 Nov; 9(11):2229-34. PubMed ID: 21883884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W; Ettingshausen CE; Auerswald G; Saguer IM; Becker S; Funk M; Heller C; Klarmann D; Klingebiel T;
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.